CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

poractant alfaWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)

Name (Synonyms) Correlation
drug258 Ayurveda Wiki 0.71
drug2612 Usual Care Wiki 0.45

Correlated MeSH Terms (3)

Name (Synonyms) Correlation
D055371 Acute Lung Injury NIH 0.10
D012127 Respiratory Distress Syndrome, Newborn NIH 0.10
D012128 Respiratory Distress Syndrome, Adult NIH 0.09

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Randomized Controlled Phase II Trial of Poractant Alfa (Curosurf®) by Fiberoptic Bronchoscopy-directed Endobronchial Administration in Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 Viral Pneumonia

Surfactant replacement therapy (SRT) improves oxygenation and survival in NRDS and some infant ARDS. SRT was tried in adult ARDS with conflicting results. Research by Filoche and Grotberg helped to understand the failure of previous clinical trials and yielded a strong scientific rationale for SRT success, now allowing to design a new administration protocol for SRT in adults, to be tested by this clinical trial in COVID-19 adult ARDS patients. Patients will be randomized to receive either a bronchial fibroscopy alone (with aspiration of secretions) or a bronchial fibroscopy with administration of 3 mL/kg of a solution of poractant alpha diluted to 16 mg/mL and distributed into each of the 5 lobar bronchi.

NCT04384731 COVID-19 ARDS, Human Drug: poractant alfa
MeSH:Respiratory Distress Syndrome, Newborn Respiratory Distress Syndrome, Adult Acute Lung Injury

Primary Outcomes

Measure: Evolution of the PaO2 / FiO2 ratio between the measurements taken before (t0) and one hour after the end of the invasive procedure (H1).

Time: 1 hour post treatment

Secondary Outcomes

Measure: Oxygenation : PaO2 / FiO2 ratio.

Time: up to Day 1 and up to Day 7

Measure: Oxygenation : area under the PaO2 / FiO2 curve.

Time: up to Day 1 and up to Day 7

Measure: Oxygenation : area under the SpO2 curve.

Time: up to Hour 1 and up to Hour 24

Measure: Evolution of thoraco-pulmonary compliance (mL / mbar) between before and one hour after the procedure.

Time: 1 hour

Measure: Overall survival rate

Time: at 28 days, 56 days.

Measure: Mortality rate at discharge from the intensive care unit.

Time: through study completion, an average of 6 months.

Measure: Mortality rate at discharge from the hospital.

Time: through study completion, an average of 6 months.

Measure: Number of ventilator-free days

Time: Day 28, Day 56

Measure: Number of prone position sessions.

Time: up to 56 days

Measure: Time between inclusion and the last prone position session.

Time: up to 56 days

No related HPO nodes (Using clinical trials)